Thomas M Abate Net Worth

The estimated Net Worth of Thomas M Abate is at least $4.64 Million dollars as of 7 May 2013. Thomas Abate owns over 15,000 units of Edwards Lifesciences Corp stock worth over $4,210,274 and over the last 19 years Thomas sold EW stock worth over $427,695.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Thomas Abate EW stock SEC Form 4 insiders trading

Thomas has made over 17 trades of the Edwards Lifesciences Corp stock since 2011, according to the Form 4 filled with the SEC. Most recently Thomas exercised 15,000 units of EW stock worth $329,400 on 7 May 2013.

The largest trade Thomas's ever made was exercising 60,000 units of Edwards Lifesciences Corp stock on 26 July 2012 worth over $1,310,400. On average, Thomas trades about 6,148 units every 18 days since 2006. As of 7 May 2013 Thomas still owns at least 61,689 units of Edwards Lifesciences Corp stock.

You can see the complete history of Thomas Abate stock trades at the bottom of the page.

What's Thomas Abate's mailing address?

Thomas's mailing address filed with the SEC is C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE, CA, 92614.

Insiders trading at Edwards Lifesciences Corp

Over the last 22 years, insiders at Edwards Lifesciences Corp have traded over $94,964,396 worth of Edwards Lifesciences Corp stock and bought 47,398 units worth $3,992,090 . The most active insiders traders include Michael A Mussallem, Donald E Jr Bobo und Steven R Loranger. On average, Edwards Lifesciences Corp executives and independent directors trade stock every 8 days with the average trade being worth of $1,126,057. The most recent stock trade was executed by Donald E Jr Bobo on 11 September 2024, trading 5,000 units of EW stock currently worth $226,400.

What does Edwards Lifesciences Corp do?

edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.

Complete history of Thomas Abate stock trades at Edwards Lifesciences Corp

Edwards Lifesciences Corp executives and stock owners

Edwards Lifesciences Corp executives and other stock owners filed with the SEC include:

• Michael Mussallem,
  Chairman of the Board, Chief Executive Officer
• Scott Ullem,
  Chief Financial Officer, Corporate Vice President
• Larry Wood,
  Corporate Vice President - Transcatheter Aortic Valve Replacement
• Donald Bobo,
  Corporate Vice President - Strategy and Corporate Development
• Catherine Szyman,
  Corporate Vice President - Critical Care
• Jean-Luc Lemercier,
  Corporate Vice President - EMEA (Europe, Middle East and Africa)
• Michael A. Mussallem,
  Chairman & CEO
• Jean-Luc Lemercier,
  Corp. VP of Europe, Middle East, Africa, Canada & Latin America
• Scott B. Ullem,
  Corp. VP & CFO
• Larry L. Wood,
  Corp. VP of Transcatheter Aortic Valve Replacement
• Donald E. Bobo Jr.,
  Corp. VP of Strategy & Corp. Devel.
• Heisz Stone,
  Independent Director
• William Link,
  Independent Director
• Kieran Gallahue,
  Independent Director
• Steven Loranger,
  Independent Director
• Nicholas Valeriani,
  Independent Director
• Martha Marsh,
  Lead Independent Director
• Paul LaViolette,
  Director
• Ramona Sequeira,
  Director
• Daveen Chopra,
  Corporate Vice President - Surgical Structural Heart
• Huimin Wang,
  Corporate Vice President - Japan, Asia and Pacific
• Christine Z. McCauley,
  Corp. VP of HR
• Dirksen J. Lehman,
  Corp. VP of Public Affairs
• Arnold A. Pinkston,
  Corp. VP & Gen. Counsel
• Mark Wilterding,
  VP of Investor Relations
• Dr. Todd J. Brinton,
  Corp. VP of Advanced Technology & Chief Scientific Officer
• Patrick B Verguet,
  CVP, Europe
• John T Cardis,
  Director
• Schack Wesley W Von,
  Director
• Daniel J. Lippis,
  CVP, JAPAC
• Carlyn D Solomon,
  CVP, Critical Care & Vascular
• David E I Pyott,
  Director
• Michael R Bowlin,
  Director
• Bruce P Garren,
  Corp VP, Gen Counsel & Secty
• Barbara J Mcneil,
  Director
• Robert Alexander Ingram,
  Director
• John H Jr Kehl,
  Corp VP, Strategy & Bus Dev
• Thomas M Abate,
  CVP, CFO and Treasurer
• Christine Z Mc Cauley,
  CVP, Human Resources
• Robert C Reindl,
  Corp VP, Human Resources
• Aimee S Weisner,
  CVP, General Counsel
• Vernon R Jr Loucks,
  Director
• Paul C Redmond,
  CVP, CardioVations Surgcl Sys
• Corinne H Nevinny,
  CVP, Chief Financial Officer
• Philip M Neal,
  Director
• Stuart L Foster,
  Corp VP, Technology/Discovery
• John Alexander Martin,
  CVP, North America
• Anita Bessler,
  Corp VP, Global Franchise Mgmt
• Randel William Woodgrift,
  Corp VP, Manufacturing Ops
• J Randall Nelson,
  Corp VP, North America
• David T Feinberg,
  Director
• Robert W.A. Sellers,
  SVP, Corporate Controller
• Bernard J Zovighian,
  CEO
• Wayne Markowitz,
  GM & SVP, Surgical
• Leslie C. Davis,
  Director